Published in Lab Business Week, September 24th, 2006
A portion of the proceeds of the sale was used to increase Arrowhead's ownership position in its majority-owned subsidiary, Calando Pharmaceuticals.
Under the terms of the agreement, Knott Partners and Potomac Capital purchased 102,250 and 102,668 shares, respectively of restricted common stock at $4.88 per share which represents the 10-day trailing average price from August 4, the date Arrowhead's board approved the transaction.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.